Literature DB >> 11056591

Policies on faculty conflicts of interest at US universities.

M K Cho1, R Shohara, A Schissel, D Rennie.   

Abstract

CONTEXT: Despite federal regulations on faculty conflicts of interest in federally funded research, academic-industry ties are common, and evidence exists that financial considerations bias the research record. Public scrutiny of these ties is increasing, especially in cases where researchers have financial interests in the corporate sponsors of their clinical research.
OBJECTIVE: To review policies on conflict of interest at major biomedical research institutions in the United States.
DESIGN: Cross-sectional survey and content analysis study conducted from August 1998 to February 2000. SETTING AND PARTICIPANTS: The 100 US institutions with the most funding from the National Institutes of Health in 1998 were initially sampled; policies from 89 institutions were available and included in the analysis. MAIN OUTCOME MEASURES: Process for disclosure, review, and management of conflicts of interest and specified management strategies or limitations, according to the institutions' faculty/staff conflict of interest policies.
RESULTS: Content of the conflict of interest policies varied widely across institutions. Fifty-five percent of policies (n = 49) required disclosures from all faculty while 45% (n = 40) required them only from principal investigators or those conducting research. Nineteen percent of policies (n = 17) specified limits on faculty financial interests in corporate sponsors of research, 12% (n = 11) specified limits on permissible delays in publication, and 4% (n = 4) prohibited student involvement in work sponsored by a company in which the faculty mentor had a financial interest.
CONCLUSIONS: Most policies on conflict of interest in our sample of major research institutions in the United States lack specificity about the kinds of relationships with industry that are permitted or prohibited. Wide variation in management of conflicts of interest among institutions may cause unnecessary confusion among potential industrial partners or competition among universities for corporate sponsorship that could erode academic standards. It is in the long-term interest of institutions to develop widely agreed-on, clear, specific, and credible policies on conflicts of interest. JAMA. 2000;284:2203-2208.

Entities:  

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Year:  2000        PMID: 11056591     DOI: 10.1001/jama.284.17.2203

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  44 in total

1.  Conflict of interest.

Authors:  B L Zaret
Journal:  J Nucl Cardiol       Date:  2001 Mar-Apr       Impact factor: 5.952

2.  Attacks on science: the risks to evidence-based policy.

Authors:  Linda Rosenstock; Lore Jackson Lee
Journal:  Am J Public Health       Date:  2002-01       Impact factor: 9.308

Review 3.  The unhealthy alliance between academia and corporate America.

Authors:  S Andreopoulos
Journal:  West J Med       Date:  2001-10

4.  Dancing with the porcupine: rules for governing the university-industry relationship.

Authors:  S Lewis; P Baird; R G Evans; W A Ghali; C J Wright; E Gibson; F Baylis
Journal:  CMAJ       Date:  2001-09-18       Impact factor: 8.262

5.  [Psychiatrists and the pharmaceutical industry].

Authors:  H Helmchen
Journal:  Nervenarzt       Date:  2003-11       Impact factor: 1.214

Review 6.  What do we really know about conflicts of interest in biomedical research?

Authors:  Teddy D Warner; John P Gluck
Journal:  Psychopharmacology (Berl)       Date:  2003-11-18       Impact factor: 4.530

7.  Working with the private sector: the need for institutional guidelines.

Authors:  Gill Walt; Ruairi Brugha; Andy Haines
Journal:  BMJ       Date:  2002-08-24

8.  How to dance with porcupines: rules and guidelines on doctors' relations with drug companies.

Authors:  Elizabeth Wager
Journal:  BMJ       Date:  2003-05-31

9.  Conflict of interest: it is ethical for an investigator to also be the primary care-giver in a clinical trial.

Authors:  Mark Bernstein
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

10.  Integrating bioethics into clinical and translational science research: a roadmap.

Authors:  Robyn S Shapiro; Peter M Layde
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.